Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

postmenopausal osteoporosis

- PMLiVE

Amgen’s Sensipar follow-up clears phase III trial

AMG 416 meets objectives in hyperparathyroidism

- PMLiVE

Amgen and Boehringer drugs win FDA breakthrough status

Leukaemia drug and Pradaxa antidote will benefit from accelerated regulatory processes

Kite Pharma once again looks to Amgen

William Go and Jeff Aycock fourth and fifth senior figures to join from Amgen this year

- PMLiVE

UCB taps EU for €75m in R&D funding

Agrees innovative risk-sharing finance deal with European Investment Bank

- PMLiVE

Epilepsy takes centre stage in UK

National Epilepsy Week aims to raise awareness of the neurological condition

- PMLiVE

Amgen appoints ex US surgeon general

Steven Galson is also a former director of the FDA’s Center for Drug Evaluation and Research

- PMLiVE

Amgen and AZ’s psoriasis antibody clears phase III trial

Brodalumab meets its targets in the AMAGINE-1 study

- PMLiVE

Amgen cholesterol antibody shines in rare disease trial

Evolocumab passes late-stage study

- PMLiVE

Pharma’s winners and losers in 2013

Roche, Johnson & Johnson and Amgen rise up the PMLiVE Top Pharma List rankings

- PMLiVE

UCB names Jean-Christophe Tellier as Doliveux’s successor

He will take over take over leadership at the Belgium pharma company next year

- PMLiVE

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Sees combination potential for cancer prospect

- PMLiVE

UCB to sell Biogen Idec’s MS drugs in Asia

Includes Tysabri and Tecfidera

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links